BirdRock Bio (formerly Ruiyi, Anaphore), was founded in 2009, when Anaphore Pharmaceuticals acquired the tetranectin protein scaffold platform from Borean Pharma in Denmark. Bird Rock Bio is a clinical-stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Developing first-in-class, best-in-class therapeutic antibodies, with significant clinical and commercial differentiation, against biologic targets with substantial human proof of mechanism.